Commercially available probiotic drinks containing Lactobacillus casei DN-114001 reduce antibiotic-associated diarrhea

Table 1 Basic data (mean ± SD or percentage) of patients in the first study

Variable	Actimel group (ward A5)	Controls (wards A6/A7)	P value
n	107	151
Age (yr)	70.8 ± 15.6	70.8 ± 16.5	NS
Male gender	48.6%	52.3%	NS
PST 0 or 1	52.3%	56.6%	NS
BMI	25.7 ± 4.2	26.1 ± 4.8	NS
Creatinine (mg/dL)	1.2 ± 0.8	1.1 ± 0.6	NS
Albumine (mg/dL)	3.5 ± 0.4	3.5 ± 0.4	NS
Diagnosis (site of infection/sepsis)	Pulmonary: 55.7% Genitourinary: 26.4% Biliary: 2.8% Sepsis: 5.7% Diverticulitis: 2.8% Dermal: 2.8% Misc.: 3.7%	Pulmonary: 50.0% Genitourinary: 22.0% Biliary: 8.0% Sepsis: 1.3% Diverticulitis: 2.7% Dermal: 4.0% Misc.: 12.0%	NS
Antibiotics	Ampicillin: 26.4% Cefuroxime: 23.5% Ceftriaxone: 12.2% Ciprofloxacin: 16.0% Clarithromycin: 12.2% Tazobactam: 3.8% Levofloxacin: 6.6% Moxifloxacin: 3.8% Metronidazole: 3.7% Clindamycin: 0.0% Cotrimoxazole: 0.9%	Ampicillin: 19.3% Cefuroxime: 18.7% Ceftriaxone: 10.7% Ciprofloxacin: 20.0% Clarithromycin: 6.7% Tazobactam: 2.7% Levofloxacin: 2.7% Moxifloxacin: 0.0% Metronidazole: 6.7% Clindamycin: 3.3% Cotrimoxazole: 4.9%	NS
Days of treatment	7.3 ± 4.2	6.1 ± 3.6	0.008

NS: No significance; BMI: Body mass index.